Constituting 15%-20% of all breast cancers (BCs), triple-negative breast cancer (TNBC) is characterized by the absence of estrogen and progesterone receptors and the non-amplification of the ERBB2 gene, which encodes human epidermal growth factor receptor 2 (HER2) [2]. Here, ERBB2 is linked to triple-negative breast carcinoma.